Janux Therapeutics (JANX) Capital Expenditures (2021 - 2026)
Janux Therapeutics (JANX) reported Capital Expenditures of $273000.0 for Q1 2026, down 26.42% year-over-year from $371000.0 in Q1 2025, and down 71.02% quarter-over-quarter from $942000.0 in Q4 2025.
Janux Therapeutics (JANX) Capital Expenditures (2021 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has 6 years of Capital Expenditures data on file, last reported at $273000.0 in Q1 2026.
- Capital Expenditures for Q1 2026 came in at $273000.0, down 26.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $945000.0 (up 29.45% YoY), and the FY2025 annual result was $1.0 million, up 190.53% from the prior year.
- Capital Expenditures eased to $273000.0 in Q1 2026 per JANX's latest filing, from $942000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $2.5 million in Q3 2022 and troughed at -$743000.0 in Q3 2025.
- A 5-year average of $515750.0 and a median of $304500.0 in 2024 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2022 and 2024: Capital Expenditures surged 36925.0% in 2022, then tumbled 733.33% in 2024.
- A 5-year view of Capital Expenditures shows it stood at $2.1 million in 2022, then tumbled by 114.49% to -$298000.0 in 2023, then jumped by 206.38% to $317000.0 in 2024, then surged by 197.16% to $942000.0 in 2025, then plunged by 71.02% to $273000.0 in 2026.
- Business Quant data shows JANX's Capital Expenditures at $273000.0 in Q1 2026, $942000.0 in Q4 2025, and -$743000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Janux Therapeutics | 892.99 Mn | 892.99 Mn | - | 273,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 273,000.00 |
| Mar 31, 2026 | 273,000.00 |
| Dec 31, 2025 | 942,000.00 |
| Dec 31, 2025 | 942,000.00 |
| Sep 30, 2025 | -743,000.00 |
| Sep 30, 2025 | -743,000.00 |
| Jun 30, 2025 | 473,000.00 |
| Jun 30, 2025 | 473,000.00 |
| Mar 31, 2025 | 371,000.00 |
| Mar 31, 2025 | 371,000.00 |
| Dec 31, 2024 | 317,000.00 |
| Dec 31, 2024 | 317,000.00 |
| Sep 30, 2024 | -250,000.00 |
| Sep 30, 2024 | -250,000.00 |
| Jun 30, 2024 | 292,000.00 |
| Jun 30, 2024 | 292,000.00 |
| Dec 31, 2023 | -298,000.00 |
| Dec 31, 2023 | -298,000.00 |
| Sep 30, 2023 | -30,000.00 |
| Sep 30, 2023 | -30,000.00 |